Nan Fung Group Holdings Ltd
In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 14, 2026), Nan Fung Group Holdings Ltd reported 24 stock positions worth $121.3 million. Its top holding was Evommune (EVMN) at 27.3% of the portfolio, followed by Maplight Therapeutics (MPLT, 16.3%) and LB Pharmaceuticals (LBRX, 12.8%). Compared with Q4 2025, it opened 2 new positions, sold out of 5, added to 1 and reduced 4. The biggest buy was LB Pharmaceuticals (LBRX, shares +110%) and the biggest sale Madrigal Pharmaceuticals (MDGL, shares −52%).
- Most Recent 13F
- Q2 2026
- Location
- KAI TAK, K3
- CIK
- 0001782539
- Portfolio Value
- $121.3M (Q1 2026)
- SEC Filing
- 0001012975-26-000423 ↗ filed May 14, 2026
Holdings Value
Holdings 24 stocks · $121.3M
| EVMN Evommune Inc. | 27.32% | 1,441,032 | $33.1M | No change |
| MPLT Maplight Therapeutics Inc. | 16.28% | 971,253 | $19.7M | No change |
| LBRX LB Pharmaceuticals Inc. | 12.82% | 630,657 | $15.6M | Add +110.2% |
| OCS Oculis Holding AG | 7.69% | 350,745 | $9.3M | Reduce -31.9% |
| INCY Incyte Corp. | 4.17% | 53,742 | $5.1M | Reduce -8.9% |
| ONC Beone Medicines Ltd.-ADR | 3.85% | 15,722 | $4.7M | No change |
| RYTM Rhythm Pharmaceuticals Inc. | 3.52% | 49,120 | $4.3M | No change |
| CELC Celcuity Inc. | 2.66% | 28,300 | $3.2M | New |
| ASND Ascendis Pharma A/S | 2.57% | 13,600 | $3.1M | No change |
| PCOR Procore Technologies Inc. | 2.51% | 53,299 | $3.0M | No change |
| MDGL Madrigal Pharmaceuticals Inc. | 2.45% | 5,672 | $3.0M | Reduce -52.2% |
| KYMR Kymera Therapeutics Inc. | 2.12% | 30,875 | $2.6M | No change |
| ACAD Acadia Pharmaceuticals Inc. | 1.89% | 102,984 | $2.3M | No change |
| HELP Cybin Inc. | 1.82% | 460,000 | $2.2M | No change |
| ARGX Argenx SE - ADR | 1.69% | 2,800 | $2.0M | No change |
| RVMD Revolution Medicines Inc. | 1.54% | 19,253 | $1.9M | No change |
| RXRX Recursion Pharmaceuticals-A | 1.51% | 595,287 | $1.8M | No change |
| INSM Insmed Inc. | 0.89% | 6,580 | $1.1M | New |
| ETHA iShares Ethereum Trust ETF | 0.66% | 50,549 | $800K | No change |
| HRMY Harmony Biosciences Holdings | 0.62% | 27,049 | $758K | No change |
| TRDA Entrada Therapeutics Inc. | 0.51% | 49,082 | $619K | No change |
| IBIT iShares Bitcoin Trust ETF | 0.51% | 15,968 | $613K | No change |
| RANI Rani Therapeutics Holdings Class A | 0.30% | 493,584 | $363K | No change |
| BOLT Bolt Biotherapeutics Inc. | 0.10% | 29,250 | $118K | Reduce -49.9% |
Portfolio Sells Q4 2025 → Q1 2026
| MDGL Madrigal Pharmaceuticals Inc. | Reduce -52.2% | 2.45% | −3.74 |
| LAB Standard Biotools Inc. | Sold out | 0.00% | −2.16 |
| OCS Oculis Holding AG | Reduce -31.9% | 7.69% | −1.51 |
| INCY Incyte Corp. | Reduce -8.9% | 4.17% | −1.05 |
| REPL Replimune Group Inc. | Sold out | 0.00% | −0.55 |
| BCYC Bicycle Therapeutics PLC-ADR | Sold out | 0.00% | −0.44 |
| RKLB Rocket Lab Corp. | Sold out | 0.00% | −0.24 |
| BOLT Bolt Biotherapeutics Inc. | Reduce -49.9% | 0.10% | −0.19 |
| BSLK Bolt Projects Holdings Inc. | Sold out | 0.00% | −0.03 |
Portfolio Buys Q4 2025 → Q1 2026
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 25 | $131.5M | MPLT, LBRX, EVMN, HELP, INCY |
| Q1 2026 | 24 | $121.3M | EVMN, MPLT, LBRX, OCS, INCY |
| Q4 2025 | 27 | $111.7M | EVMN, MPLT, OCS, MDGL, LBRX |
| Q3 2025 | 24 | $59.6M | OCS, MDGL, ONC, INCY, RYTM |
| Q2 2025 | 20 | $63.4M | HRMY, ILMN, OCS, INCY, ONC |
| Q1 2025 | 35 | $122.6M | HRMY, OCS, ILMN, VRNA, ZLAB |
| Q4 2024 | 35 | $116.9M | ILMN, HRMY, OCS, VRNA, ZLAB |
| Q3 2024 | 38 | $116.1M | ILMN, HRMY, GERN, MRUS, ZLAB |
| Q2 2024 | 44 | $93.7M | ILMN, HRMY, MRUS, GERN, OCS |
| Q1 2024 | 45 | $107.9M | ILMN, HRMY, ALPN, OCS, LAB |